Metabolic mechanisms are central to the onset and progression of chronic illnesses, yet their complexity poses persistent challenges in therapeutic development. To address this, Biocytogen has established and continues to expand a comprehensive portfolio of drug-targeted humanized mice and disease models for glucose and lipid metabolism disorders. These advanced preclinical models are designed to accelerate drug discovery and development for a range of metabolic disorders, including diabetes, obesity, fatty liver disease, fibrosis, and atherosclerosis.
